Conceição, Isabel http://orcid.org/0000-0003-0934-9631
Berk, John L.
Weiler, Markus
Kowacs, Pedro A.
Dasgupta, Noel R.
Khella, Sami
Chao, Chi-Chao
Attarian, Shahram
Kwoh, T. Jesse
Jung, Shiangtung W.
Chen, Jersey
Viney, Nicholas J.
Yu, Rosie Z.
Gertz, Morie
Masri, Ahmad
Cruz, Márcia Waddington
Coelho, Teresa
Funding for this research was provided by:
Ionis Pharmaceuticals, Inc.
Article History
Received: 27 June 2024
Revised: 23 July 2024
Accepted: 28 July 2024
First Online: 13 August 2024
Declarations
:
: I.C. has received financial support as primary investigator, and is a consultant to Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals Inc., and Pfizer Inc. J.L.B. has participated in an Ionis Pharmaceuticals Inc., ad hoc advisory committee. M.W. is a consultant to Akcea Therapeutics, Alnylam Pharmaceuticals, Biogen, Hoffmann-La Roche, Novo Nordisk, Pfizer, and Sobi; and has received speaker fees from Akcea Therapeutics, Alnylam Pharmaceuticals, and Biogen, and financial support for conference attendance from Akcea Therapeutics, Alnylam Pharmaceuticals, Ionis Pharmaceuticals Inc., and Pfizer Inc. P.A.K. is currently participating in the ION trial. N.R.D. is a consultant to Alnylam, Eidos, and Intellia; and has lectured for Alnylam. S.K. is a consultant to Alnylum and Ionis Pharmaceuticals Inc. C-C.C. reports no conflicts of interest. S.A. has provided consultancy for Alnylam Pharmaceuticals, AstraZeneca, and Pfizer Inc. T.J.K., S.W.J., N.J.V., and R.Z.Y. are employees of, and shareholders in Ionis Pharmaceuticals Inc. J.C. is an employee of, and shareholder in AstraZeneca. M.G. has been a consultant to Ionis Pharmaceuticals Inc./Akcea, Prothena, Sanofi, Janssen, Aptitude Health, Juno, Physicians Education Resource, AbbVie, Johnson & Johnson, Celgene, Research to Practice, and Sorrento; has received research funding from Ashfield; and has received fees for development of educational materials from i3 Health. A.M. has received research grants from Attralus, Cytokinetics, Ionis Pharmaceuticals Inc., Pfizer, Ultromics, and the Wheeler Foundation; and personal funding from Alnylam, Attralus, Bristol-Myers Squibb, Cytokinetics, Eidos, Haya, Ionis Pharmaceuticals Inc., Pfizer Inc., and Tenaya. M.W.C. is a principal investigator for the NEURO-TTRansform trial and is a consultant for Ionis Pharmaceuticals Inc. T.C. is a principal investigator for the NEURO-TTRansform trial (paid to institution) and has received financial support from Ionis Pharmaceuticals Inc., and Akcea to attend scientific meetings.
: The study protocol was approved by the institutional review board at each participating center, or by an independent ethics committee.